SCHEMBL4165474

SCHEMBL4165474

O=C(O)c1[nH]c2c(-c3ccccc3)cccc2c1CCCOc1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 18/20 1.00
BCL2 P10415 2/20 0.71
ALB P02768 1/20 0.71
PRKCD Q05655 3/20 0.69
CAMK2B Q13554 3/20 0.69
CAMK2G Q13555 3/20 0.69
MARK3 P27448 2/20 0.69
AXL P30530 2/20 0.69
NEK4 P51957 2/20 0.69
CAMK2D Q13557 2/20 0.69
MARK2 Q7KZI7 2/20 0.69
PIM3 Q86V86 2/20 0.69
HIPK2 Q9H2X6 2/20 0.69
MKNK2 Q9HBH9 2/20 0.69
MAP3K20 Q9NYL2 2/20 0.69
MAP4K5 Q9Y4K4 2/20 0.69
EEF2K O00418 1/20 0.69
BCL6 P41182 1/20 0.69
PRKAA1 Q13131 1/20 0.69
BCL2L1 Q07817 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161638 0.96 MCL1 (0.92) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4161471 0.94 MCL1 (0.92) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4154013 0.94 MCL1 (1.00) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4161285 0.94 MCL1 (0.88) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4165535 0.94 MCL1 (0.88) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4164263 0.94 MCL1 (0.88) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4156989 0.93 MCL1 (0.86) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4166097 0.93 MCL1 (0.86) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4166750 0.92 MCL1 (0.88) MCL1BCL2ALBPRKCDCAMK2B
SCHEMBL4170129 0.92 MCL1 (0.85) MCL1BCL2ALBPRKCDCAMK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 EP claimed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 US claimed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 US claimed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP claimed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 US claimed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO claimed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 US disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 WO disclosed
EP-3243814-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 EP disclosed
US-9359296-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2016-06-07 US disclosed
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC (US) 2015-10-08 US disclosed
US-9035047-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2015-05-19 US disclosed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 US disclosed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 US disclosed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP disclosed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885BCL2 14/4885ALB 3819/4885
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, FLT3, ABL1 MCL1 1/4885BCL2 43/4885ALB 4601/4885
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885BCL2 14/4885ALB 3819/4885
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885BCL2 14/4885ALB 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.